Report of Foreign Issuer (6-k)

---

---

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.  20549

______________________

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

 

For the month of August 2014

 

Commission File Number: 001-36073

 

                  Enzymotec Ltd.                   

 

(Translation of registrant’s name into English)

 

Sagi 2000 Industrial Area

P.O. Box 6

 Migdal Ha’Emeq 2310001, Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x                                          Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o                                           No x

 

        If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-________

 

 

 

---

 

 

EXPLANATORY NOTE

 

On Tuesday, August 19, 2014, Enzymotec Ltd. issued a press release entitled “Enzymotec Ltd. Announces an Annual General Meeting of Shareholders.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

 

2

---

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	ENZYMOTEC LTD.
Date: August 19, 2014	By:	/s/ Oren Bryan
		Name: Oren Bryan
		Title:   Chief Financial Officer

 

 

3

---

 

 

EXHIBIT INDEX

 

The following exhibit is filed as part of this Form 6-K:

                              

Exhibit   99.1

Description   Press release dated August 19, 2014 entitled “Enzymotec Ltd. Announces an Annual General Meeting of Shareholders.”

4

---

---

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

---

Exhibit 99.1

 

Enzymotec Ltd. Announces an Annual

General Meeting of Shareholders 

---

MIGDAL HA’EMEQ, ISRAEL, August 19, 2014—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), today announced that it will hold an Annual General Meeting of Shareholders on Monday, September 29, 2014. The record date for shareholders entitled to vote at the meeting is Monday, August 25, 2014.

 

The meeting is being called for the following purposes:

(1)(a)	To reelect Mr. Yossi Peled to serve as a director of the Company for a three year term;
(1)(b)	To reelect Mr. Jacob (Yaacov) Bachar to serve as a director of the Company for a three year term;
(2)	To approve the reappointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the Company's independent, external auditors for the year ending December 31, 2014 and until the next annual general meeting of shareholders, and to authorize the Company’s Board of Directors to set the fees to be paid to such auditors; and
(3)	To act upon such other matters as may properly come before the meeting or any adjournment or postponement thereof.

Approval of each of the above proposals requires the affirmative vote of the holders of a majority of the voting power represented at the meeting in person or by proxy and voting on the proposal.   

The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least 25% of the voting rights in the Company constitute a quorum for purposes of the meeting. In the absence of the requisite quorum of shareholders at the meeting, the meeting will be adjourned to the same day in the next week, at the same time and place, unless otherwise determined at the meeting in accordance with the Company’s articles of association. At such adjourned meeting the presence of at least two shareholders in person or by proxy (regardless of the voting power represented by their shares) will constitute a quorum.

 

Additional Information and Where to Find It

 

In connection with the meeting, the Company will make available to its shareholders of record a proxy statement describing the time and place, and other logistical information related to the meeting, and the proposals to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each proposal. The Company is also furnishing copies of the proxy statement and proxy card to the Securities and Exchange Commission, or SEC, in a Report of Foreign Private Issuer on Form 6-K, which may be obtained for free from the SEC’s website at www.sec.gov and will be available on the Company’s  website at www.enzymotec.com.

About the Company

 

The Company is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.

For more information, visit www.enzymotec.com.

 

Press Contact:

 

Katie Turner, ICR

[phone]

[e-mail] 

 

John Mills, ICR

[phone]

[e-mail]

 

---

---